US Patent 11603529 Variant RNAi
Patent 11603529 was granted and assigned to Genzyme on March, 2023 by the United States Patent and Trademark Office.
All edits
Edits on 25 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
116035290
Date of Patent
March 14, 2023
0Patent Application Number
166490420
Date Filed
September 21, 2018
0Patent Primary Examiner
Edits on 15 Mar, 2023
Golden AI
Edits made to:
Infobox (+16 properties)
Article (+420 characters)
US Patent 11603529 Variant RNAi
Article
Provided herein are RNAi molecules for treating Huntington's disease. Further provided herein are expression cassettes, vectors (e.g., rAAV, recombinant adenoviral, recombinant lentiviral, and recombinant HSV vectors), cells, viral particles, and pharmaceutical compositions containing the RNAi. Yet further provided herein are methods and kits related to the use of the RNAi, for example, to treat Huntington's disease.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
116035290
Date of Patent
March 14, 2023
0Patent Application Number
166490420
Date Filed
September 21, 2018
0Patent Primary Examiner
Find more entities like US Patent 11603529 Variant RNAi
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
